-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Monitoring and Reversal of Direct Oral Anticoagulants

Program: Education Program
Session: Evolving Issues in Anticoagulation
Saturday, December 5, 2015, 4:00 PM-5:30 PM
Tangerine 1 (WF1), Level 2 (Orange County Convention Center)
Sunday, December 6, 2015, 7:30 AM-9:00 AM
Tangerine 1 (WF1), Level 2 (Orange County Convention Center)

Adam Cuker, MD, MS

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Disclosures: Cuker: T2 Biosystems: Research Funding ; CSL Behring: Consultancy ; Genzyme: Consultancy ; Bracco: Consultancy . Off Label Use: Fondaparinux and bivalirudin for the treatment of acute HIT..

See more of: Evolving Issues in Anticoagulation
See more of: Education Program
Previous Presentation | Next Presentation >>